Please ensure Javascript is enabled for purposes of website accessibility

Can Sleep Apnea Wake Up Fitbit Stock?

By Rick Munarriz - Jun 21, 2017 at 10:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The wearable-tech pioneer hopes that sleep apnea detection will breathe new life into the shares.

Fitbit (FIT) is struggling these days, but it's hoping that helping improve sleep quality could be the ticket to a turnaround. The leading maker of dedicated activity-monitoring wearables was on CNBC yesterday, revealing that it's developing tools to diagnose and monitor sleep apnea -- a common sleep disorder that affects more than 18 million Americans. 

Fitbit stock has been a disaster. The stock dipped below $5 for the first time late last week, falling more than 90% since hitting its post-IPO highs two summers ago. The former market darling has suffered through back-to-back quarters of double-digit revenue declines, and history isn't kind to trendy device makers once their flagship products begin to lose steam. Making its wrist huggers more functional should help, especially for a malady with serious ramifications that often goes undiagnosed.

Fitbit wearer jumping rope.

Image source: Fitbit.

Sleep on it

Sleep apnea occurs when a person's breathing is interrupted several times during the night, limiting the oxygen supply to the brain. It's a common disorder with older overweight males who snore and, if left untreated, can result in high blood pressure, diabetes, strokes, and a lack of energy and focus during the day. 

Fitbit's tools, if successful, won't cure or even treat sleep apnea. Fitbit would simply help detect sleep apnea, something that until now is typically diagnosed after an overnight polysomnogram at a sleep study center. If diagnosed, the person would still likely need CPAP masks, surgery, or lifestyle changes to turn things around. However, the key here is that Fitbit trackers would be more useful than merely tracking steps or encouraging more active lifestyles. 

Anything would help Fitbit at this point. Revenue plummeted 41% to $298.9 million in Fitbit's first quarter, and it's coming off its second straight quarterly loss. Fitbit's guidance calls for another quarterly deficit and its third straight period of double-digit revenue declines for the quarter ending next week. New products used to be the lifeblood of growth at Fitbit, but March's release of Alta HR hasn't made much of a difference.

A legitimate medical application can change the perceived value proposition of the wristbands. If Fitbit is able to detect sleep apnea and then monitor to the sleep quality of those diagnosed with the disorder, it can become more than just novelty jewelry. It would also help increase Fitbit's standing in the corporate-wellness market, a promising enterprise niche that still accounts for less than 10% of Fitbit's revenue. Fitbit stock needs to shake itself out of its problematic slumber, and medical applications could be the key to establishing a second act for the market laggard.

Rick Munarriz owns shares of Fitbit. The Motley Fool owns shares of and recommends Fitbit. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fitbit, Inc. Stock Quote
Fitbit, Inc.
FIT

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.